These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19336826)

  • 21. Vaccine manufacturers cannot be sued over design defects, US Supreme Court rules.
    Dyer C
    BMJ; 2011 Feb; 342():d1292. PubMed ID: 21355024
    [No Abstract]   [Full Text] [Related]  

  • 22. A strike against preemption.
    Nat Biotechnol; 2009 May; 27(5):397. PubMed ID: 19430422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
    Vladeck DC
    Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967
    [No Abstract]   [Full Text] [Related]  

  • 24. US Supreme Court could reshape Hatch-Waxman's same labeling requirement.
    Sullivan CG
    Future Med Chem; 2012 Jan; 4(1):7-8. PubMed ID: 22168159
    [No Abstract]   [Full Text] [Related]  

  • 25. Court rules generic drug companies not responsible for adverse outcomes.
    Kouros N
    Monash Bioeth Rev; 2013 Sep; 31(2):23-4. PubMed ID: 24844072
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmaceutical promotion and First Amendment rights.
    Troy DE; Gottlieb S
    N Engl J Med; 2008 Jul; 359(5):536; author reply 536-7. PubMed ID: 18669437
    [No Abstract]   [Full Text] [Related]  

  • 27. Intellectual property. Drug patents at the Supreme Court.
    Hemphill CS; Sampat B
    Science; 2013 Mar; 339(6126):1386-7. PubMed ID: 23520096
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmaceutical promotion to physicians and First Amendment rights.
    Kesselheim AS; Avorn J
    N Engl J Med; 2008 Apr; 358(16):1727-32. PubMed ID: 18420505
    [No Abstract]   [Full Text] [Related]  

  • 29. Regulators can challenge deals that delay generic competition, says US Supreme Court.
    McCarthy M
    BMJ; 2013 Jun; 346():f3964. PubMed ID: 23783361
    [No Abstract]   [Full Text] [Related]  

  • 30. Sequenom, the U.S. Supreme Court, and Personalized Medicine.
    Kodroff CA
    Hum Gene Ther Clin Dev; 2016 Jun; 27(2):49-52. PubMed ID: 27267566
    [No Abstract]   [Full Text] [Related]  

  • 31. Generics still unable to resolve ANDA patent issues by declaratory judgment, but is a supreme court resolution on the way?
    Eccleston LE
    Health Care Law Mon; 2006 Dec; ():3-5. PubMed ID: 17236678
    [No Abstract]   [Full Text] [Related]  

  • 32. On access and accountability--two Supreme Court rulings on generic drugs.
    Boumil MM; Curfman GD
    N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
    [No Abstract]   [Full Text] [Related]  

  • 33. Supreme Court hears Maine Rx case.
    Young D
    Am J Health Syst Pharm; 2003 Mar; 60(6):544. PubMed ID: 12659053
    [No Abstract]   [Full Text] [Related]  

  • 34. Data-mining law struck down. Supreme court sides with drug companies in Vermont ruling.
    Carlson J
    Mod Healthc; 2011 Jun; 41(26):8-9. PubMed ID: 21853604
    [No Abstract]   [Full Text] [Related]  

  • 35. Epilepsy, driving and the pharmaceutical industry--legal responsibility.
    Reuben W
    Med Law; 2002; 21(3):639-50. PubMed ID: 12437208
    [No Abstract]   [Full Text] [Related]  

  • 36. Free speech rights outweigh restrictions on promoting drugs off label, court rules.
    Roehr B
    BMJ; 2012 Dec; 345():e8324. PubMed ID: 23220261
    [No Abstract]   [Full Text] [Related]  

  • 37. Supreme Court to decide whether payments by patent holders to delay production of generics are anticompetitive.
    Roehr B
    BMJ; 2012 Dec; 345():e8464. PubMed ID: 23236054
    [No Abstract]   [Full Text] [Related]  

  • 38. The Supreme Court's interpretation of the biosimilars statute and the value of certainty.
    Royzman I; Monroe-Yavneh N
    Nat Biotechnol; 2017 Oct; 35(10):916-919. PubMed ID: 29019999
    [No Abstract]   [Full Text] [Related]  

  • 39. FDA preemption of drug and device labeling: who should decide what goes on a drug label?
    Valoir T; Ghosh S
    Health Matrix Clevel; 2011; 21(2):555-98. PubMed ID: 22145525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Merck KGaA v. Integra Lifesciences I, Ltd: implications of the supreme court's decision for the people who matter most...the consumer.
    Jaquette I
    Am J Law Med; 2007; 33(1):97-117. PubMed ID: 17547356
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.